In longevity care, AC-Selank-NH2 is positioned as a non-sedating anxiolytic–nootropic that helps preserve mental clarity, focus, and stress resilience as patients age. In Celexir’s catalog, it’s used for stress-related cognitive dysfunction and mood imbalance, supporting “brain-first” aging alongside sleep, metabolic, and inflammation management.
Mechanistically, Selank is a tuftsin-derived heptapeptide (TKPRPGP) engineered for stability; preclinical work shows it modulates GABAergic signaling, influences monoamines, and regulates BDNF expression—pathways tied to attention, learning, and neuroplasticity. Studies report rapid changes in GABA-pathway gene expression and prevention of stress-related BDNF perturbations in cortex/hippocampus, offering a biologically coherent basis for cognitive support in aging.
Clinically, Selank’s evidence base is strongest in Russia and neighboring regions: small trials and translational studies describe anxiolytic effects (comparable to low-dose benzodiazepines) without sedation, potential adjunctive synergy with diazepam, and improvements in anxiety-asthenic states. While these signals align with longevity goals (maintaining cognitive reserve under stress), larger multicenter RCTs are still needed; position usage as investigational with informed consent and objective tracking (attention tasks, mood/HRV).
Celexir delivery & specs: ready-to-use injectable pens, >98% purity, 2–8 °C storage, and documentation (CoA/MSDS). Catalog protocols commonly deploy 200–400 mcg daily for 7–14 days, tailored to patient context and integrated with comprehensive longevity care.